XML 62 R34.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Revenue Recognition - Additional Information (Detail) (USD $) | 3 Months Ended | 6 Months Ended | 3 Months Ended |  | 6 Months Ended |  | 0 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 3 Months Ended | 6 Months Ended | 0 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2014 | Mar. 31, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Mar. 31, 2014 Technology Transfer | Jun. 30, 2014 Technology Transfer | Jun. 30, 2014 Clinical Development | Jun. 30, 2014 Initial Commercial Sales | Sep. 04, 2013 Pfizer Incorporation Nonsoftware License Arrangement | Jan. 22, 2013 Pfizer Incorporation Nonsoftware License Arrangement | Jun. 30, 2014 Pfizer Incorporation Nonsoftware License Arrangement | Jun. 30, 2013 Pfizer Incorporation Nonsoftware License Arrangement | Jun. 30, 2014 Pfizer Incorporation Nonsoftware License Arrangement | Jun. 30, 2013 Pfizer Incorporation Nonsoftware License Arrangement | Dec. 31, 2012 Pfizer Incorporation Nonsoftware License Arrangement | Jun. 30, 2014 Orencia Royalties from Bristol | Jun. 30, 2013 Orencia Royalties from Bristol | Jun. 30, 2014 Orencia Royalties from Bristol | Jun. 30, 2013 Orencia Royalties from Bristol | Jan. 30, 2014 BioMarin Pharmaceutical, Inc. Asset Purchase Agreement | Mar. 31, 2014 BioMarin Pharmaceutical, Inc. Asset Purchase Agreement | Jun. 30, 2014 BioMarin Pharmaceutical, Inc. Asset Purchase Agreement | Jun. 30, 2014 BioMarin Pharmaceutical, Inc. Asset Purchase Agreement Clinical Development | Jun. 30, 2014 BioMarin Pharmaceutical, Inc. Asset Purchase Agreement Initial Commercial Sales
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront Payment received under license agreement |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Potential milestone payments to be received |  |  |  |  |  |  |  | 60,000,000 | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 160,000,000 |  |
Percentage relate to clinical development from Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37.00% | 63.00%
Provision for refund |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |
License agreement, revenue recognized |  |  |  | 2,115,000 |  | 0 |  |  |  |  |  | 0 | 69,000 | 0 | 124,000 | 4,876,000 |  |  |  |  |  | 2,000,000 |  |  |
Non-refundable up-front payment |  |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to be received upon signing of agreement |  |  |  | 126,375 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized under revenue recognition, up front payment |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated selling price |  |  |  |  |  |  | 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration allocated to transaction |  |  |  |  |  |  | 11,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | 60,000,000 |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  | 64,000,000 |  | 64,000,000 |  |  |  |  |  |  |  |  |  |  |
Royalty revenue |  |  | 4,495,357 | 1,991,166 | 9,017,081 |  |  |  |  |  |  |  |  |  |  |  | 0 | 4,285,000 | 0 | 8,131,000 |  |  |  |  |
Percentage of royalty revenue, remittance to the University of Michigan |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of royalty revenue |  |  | 642,736 |  | 1,219,593 |  |  |  |  |  |  |  |  |  |  |  | 0 | 643,000 | 0 | 1,220,000 |  |  |  |  |
Revenue from sponsored research and development projects | $ 0 |  | $ 142,000 | $ 0 | $ 762,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Consideration Allocated To Transaction Rights + References No definition available. + Details
Name: | rgen_ConsiderationAllocatedToTransactionRights
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Expected Milestone Receivable + References No definition available. + Details
Name: | rgen_ExpectedMilestoneReceivable
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long Lived Assets Held for sale, Estimated Selling Cost + References No definition available. + Details
Name: | rgen_LongLivedAssetsHeldForSaleEstimatedSellingCost
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance + References No definition available. + Details
Name: | rgen_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable Upfront Cash Payment Under Collaborations Agreement + References No definition available. + Details
Name: | rgen_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment To Be Received Upon Signing Of Agreement + References No definition available. + Details
Name: | rgen_PaymentToBeReceivedUponSigningOfAgreement
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Future Milestone Payments + References No definition available. + Details
Name: | rgen_PercentageOfFutureMilestonePayments
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Additional Milestone Payments Associated With Potential Regulatory Approvals + References No definition available. + Details
Name: | rgen_PotentialAdditionalMilestonePaymentsAssociatedWithPotentialRegulatoryApprovals
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Provision For Wholesale Refunds + References No definition available. + Details
Name: | rgen_ProvisionForWholesaleRefunds
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Payment Rate + References No definition available. + Details
Name: | rgen_RoyaltyPaymentRate
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_DirectOperatingCostRoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration